EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Survival by first‐line therapy and prognostic group among men with metastatic castration‐resistant prostate cancer

Megan E V Caram iD, Kyle Kumbier, Phoebe A Tsao iD, Jennifer Burns, Jordan B Sparks iD, Kristian D Stensland iD, Zachery R Reichert, Joshi J Alumkal, Brent K Hollenbeck, Vahakn Shahinian, Alexander Tsodikov, Ted A Skolarus

Cancer Medicine · 2024

DOI: 10.1002/cam4.7334 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Megan E V Caram und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Ketoconazole, Phenylthiohydantoin, Docetaxel. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Prostate Cancer Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Metastatic castration‐resistant prostate cancer (mCRPC) is a heterogeneous disease with prognoses varying from months to years at time of castration‐resistant diagnosis. Optimal first‐line therapy for those with different prognoses is unknown.

Methods

We conducted a retrospective cohort study of men in a national healthcare delivery system receiving first‐line therapy for mCRPC (abiraterone, enzalutamide, docetaxel, or ketoconazole) from 2010 to 2017, with follow‐up through 2019. Using commonly drawn prognostic labs at start of mCRPC therapy (hemoglobin, albumin, and alkaline phosphatase), we categorized men into favorable, intermediate, or poor prognostic groups depending on whether they had none, one to two, or all three laboratory values worse than designated laboratory cutoffs. We used Kaplan–Meier methods to examine prostate specific antigen (PSA) progression‐free and overall survival (OS) according to prognostic group and first‐line therapy, and multivariable cox regression to determine variables associated with survival outcomes.

Results

Among 4135 patients, median PSA progression‐free survival (PFS) was 6.9 months (95% confidence interval [CI] 6.6–7.3), and median OS 18.8 months (95% CI 18.0–19.6), ranging from 5.7 months (95% CI 4.8–7.0) in the poor prognosis group to 31.3 months (95% CI 29.7–32.9) in the favorable group. OS was similar regardless of initial treatment received for favorable and intermediate groups, but worse for those in the poor prognostic group who received ketoconazole (adjusted hazard ratio 2.07, 95% CI 1.2–3.6). PSA PFS was worse for those who received ketoconazole compared to abiraterone across all prognostic groups (favorable HR 1.76, 95% CI 1.34–2.31; intermediate HR 1.78, 95% CI 1.41–2.25; poor HR 8.01, 95% CI 2.93–21.9).

Conclusion

Commonly drawn labs at mCRPC treatment start may aid in predicting survival and response to therapies, potentially informing discussions with care teams. First‐line treatment selection impacts disease progression for all men with mCRPC regardless of prognostic group, but impacted OS only for men with poor prognosis at treatment start.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantKetoconazolePhenylthiohydantoinDocetaxelAndrostenesMaleHumansAgedRetrospective StudiesPrognosisMiddle AgedProstate-Specific AntigenBenzamidesNitrilesAged, 80 and overProgression-Free SurvivalAntineoplastic Combined Chemotherapy ProtocolsKaplan-Meier Estimate

Stichwörter der Autor:innen

novel therapiesprognosisprostate cancer

Substanzen

KetoconazolePhenylthiohydantoinabirateroneenzalutamideDocetaxelAndrostenesProstate-Specific AntigenBenzamidesNitriles

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • VA Health Services Research & Development, Center for Clinical Management and Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA.
  • Department of Urology, University of Michigan, Ann Arbor, Michigan, USA.
  • Department of Urology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
  • Department of Surgery, Urology Section, University of Chicago, Chicago, Illinois, USA.

ORCID-Profile: Megan E V Caram, Phoebe A Tsao, Jordan B Sparks, Kristian D Stensland

Förderung

  • NCI NIH HHS
  • Prostate Cancer Foundation

Zitieren

APA

Caram, M. E. V., Kumbier, K., Tsao, P. A., Burns, J., Sparks, J. B., Stensland, K. D., Reichert, Z. R., Alumkal, J. J., Hollenbeck, B. K., Shahinian, V., Tsodikov, A., & Skolarus, T. A. (2024). Survival by first‐line therapy and prognostic group among men with metastatic castration‐resistant prostate cancer. Cancer Medicine. https://doi.org/10.1002/cam4.7334

Vancouver

Caram MEV, Kumbier K, Tsao PA, Burns J, Sparks JB, Stensland KD, et al. Survival by first‐line therapy and prognostic group among men with metastatic castration‐resistant prostate cancer. Cancer Medicine. 2024. doi:10.1002/cam4.7334

BibTeX
@article{Caram2024,
  author = {Caram, Megan E V and Kumbier, Kyle and Tsao, Phoebe A and Burns, Jennifer and Sparks, Jordan B and Stensland, Kristian D and Reichert, Zachery R and Alumkal, Joshi J and Hollenbeck, Brent K and Shahinian, Vahakn and Tsodikov, Alexander and Skolarus, Ted A},
  title = {Survival by first‐line therapy and prognostic group among men with metastatic castration‐resistant prostate cancer},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.7334}
}
Kostenlos starten →